de Boccardo 2002.

Methods	Placebo‐controlled RCT
Participants	Setting: International Multicentre (31) Countries: Argentina, Brazil, Costa Rica, Chile, Mexico Cadaveric (46%) or living donor kidney transplant Agee: 38.0 ± 12.4 years Number (treatment/control): 310 (NS/NS) Sex (% M/F): 58.6/40.4
Interventions	Treatment group Basiliximab: 20 mg days 0 and 4 Control group Placebo Baseline immunosuppression CSA: 10 mg/kg/d (day 0) and dose adjusted to predefine trough levels AZA: 1‐2 mg/kg/d Steroids: As per site standards, minimum daily dose of 5 mg at 6 months
Outcomes	Mortality Graft loss Acute rejection Malignancy
Notes	Number randomised in each group NS, calculated from given proportions 6 month follow‐up Trial on‐going Data from abstract only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated "randomised", no further information provided
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Objective outcomes	Unclear risk	"Double blind", blinding of outcome assessors not stated
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	"Double blind", blinding of outcome assessors not stated
Incomplete outcome data (attrition bias) All outcomes	High risk	Stated ITT, but not all randomised patients were analysed. Data only available from conference proceedings abstract
Selective reporting (reporting bias)	Unclear risk	Primary outcomes for this review (death, graft loss and acute rejection) have been reported, however data only available as percentages from conference proceedings abstract
Other bias	Unclear risk	Funding source not stated, data only available from conference proceedings abstract